Cargando…

Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection

The potent antituberculosis activity and long half-life of bedaquiline make it an attractive candidate for use in long-acting/extended-release formulations for the treatment of latent tuberculosis infection (LTBI). Our objective was to evaluate a long-acting injectable (LAI) bedaquiline formulation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaushik, Amit, Ammerman, Nicole C., Tyagi, Sandeep, Saini, Vikram, Vervoort, Iwan, Lachau-Durand, Sophie, Nuermberger, Eric, Andries, Koen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2019
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437534/ https://www.ncbi.nlm.nih.gov/pubmed/30745396 http://dx.doi.org/10.1128/AAC.00007-19

Ejemplares similares

Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis
por: Li, Si-Yang, et al.
Publicado: (2017)

Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy
por: Chang, Yong S., et al.
Publicado: (2023)

Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2021)

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2019)

Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis
por: Almeida, Deepak, et al.
Publicado: (2021)

Daily Dosing for Bedaquiline in Patients with Tuberculosis
por: Salinger, David H., et al.
Publicado: (2019)

Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies
por: Zhang, Nan, et al.
Publicado: (2020)

Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative Database
por: Berg, Alexander, et al.
Publicado: (2022)

TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus
por: Sarathy, Jickky Palmae, et al.
Publicado: (2020)

Rapid Diagnosis of Recurrent Paucibacillary Tuberculosis
por: Jafari, Claudia, et al.
Publicado: (2023)

Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
por: Andries, Koen, et al.
Publicado: (2014)

Morphea Simulating Paucibacillary Leprosy Clinically and Histopathologically
por: Delgado, José Saulo Torres, et al.
Publicado: (2013)

Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B
por: Skipper, Caleb P., et al.
Publicado: (2020)

Lysis of tubercle bacilli in fresh and stored sputum specimens: implications for diagnosing tuberculosis in stored and paucibacillary specimens by PCR
por: Pathak, Divya, et al.
Publicado: (2007)

In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria
por: Aguilar-Ayala, Diana A., et al.
Publicado: (2017)

Diagnostic challenges of single plaque-like lesion paucibacillary leprosy
por: Barbieri, Raquel Rodrigues, et al.
Publicado: (2014)

Study of S100 Immunostaining in Demonstrating Neural Granulomas in Paucibacillary Leprosy
por: Shenoy, Nandini, et al.
Publicado: (2018)

Using dynamic oral dosing of rifapentine and rifabutin to simulate exposure profiles of long-acting formulations in a mouse model of tuberculosis preventive therapy
por: Chang, Yong S., et al.
Publicado: (2023)

Altered cytokine profiles in relapsed paucibacillary leprosy: a case report
por: Sameshima, Tomoyuki, et al.
Publicado: (2021)

Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice
por: Irwin, Scott M., et al.
Publicado: (2016)

Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension
por: Mc Crudden, Maelíosa T.C., et al.
Publicado: (2018)

Role of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long‐Acting β (2)‐Agonists and Inhaled Corticosteroids: The OUTPUL Study
por: Ferroni, Eliana, et al.
Publicado: (2016)

BACTERIOLOGICAL STUDY OF AEROBIC ISOLATES FROM PLANTAR ULCERS OF PAUCIBACILLARY LEPROSY PATIENTS
por: Majumdar, Monalisa, et al.
Publicado: (2010)

Three drugs are unnecessary for treating paucibacillary leprosy—A critique of the WHO guidelines
por: Lockwood, Diana N. J., et al.
Publicado: (2019)

Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer
por: Converse, Paul J., et al.
Publicado: (2018)

Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism
por: Koul, Anil, et al.
Publicado: (2014)

Dual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis
por: Tasneen, Rokeya, et al.
Publicado: (2021)

Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model
por: Li, Si-Yang, et al.
Publicado: (2023)

γ-Tocotrienol suppresses growth and sensitises human colorectal tumours to capecitabine in a nude mouse xenograft model by down-regulating multiple molecules
por: Prasad, Sahdeo, et al.
Publicado: (2016)

Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline
por: Kaniga, K., et al.
Publicado: (2022)

Quantitative polymerase chain reaction in paucibacillary leprosy diagnosis: A follow-up study
por: Barbieri, Raquel R., et al.
Publicado: (2019)

Response to “Three drugs are unnecessary for treating paucibacillary leprosy—A critique of the WHO guidelines”
por: Kumar, Bhushan, et al.
Publicado: (2020)

Diagnostic performance of non-invasive, stool-based molecular assays in patients with paucibacillary tuberculosis
por: Gaur, Mohita, et al.
Publicado: (2020)

T405, a New Penem, Exhibits In Vivo Efficacy against M. abscessus and Synergy with β-Lactams Imipenem and Cefditoren
por: Rimal, Binayak, et al.
Publicado: (2022)

Maleate salts of bedaquiline
por: Zeller, Matthias, et al.
Publicado: (2021)

Chloroquine Potentiates Primaquine Activity against Active and Latent Hepatic Plasmodia Ex Vivo: Potentials and Pitfalls
por: Dembélé, Laurent, et al.
Publicado: (2020)

Coadministration of bedaquiline and pyrifazimine reduce exposure to toxic metabolite N-desmethyl bedaquiline
por: Ding, Yangming, et al.
Publicado: (2023)

6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis
por: Tong, Amy S. T., et al.
Publicado: (2017)

Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline
por: Villellas, Cristina, et al.
Publicado: (2017)

Exposure–Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma
por: Bajaj, Gaurav, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4lrj8d61mi8g5ac82mej490rj0